Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Exciting potential of pembrolizumab combined with axitinib for kidney cancer

Elizabeth Plimack • 8 Feb 2018
GU Cancers 2018
Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab Sunitinib

Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab combined with axitinib for the first-line treatment of advanced kidney cancer. Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Plimack hopes this combination can become the new frontline standard of care in renal oncology.

More from Elizabeth Plimack

3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
1:41
Molecular profiling of exceptional responders to cancer therapy
Elizabeth Plimack • 7 Apr 2021
0:57
Areas of unmet need for patients with advanced UC
Elizabeth Plimack • 7 Apr 2021
2:22
JAVELIN Bladder 100: practice-changing data
Elizabeth Plimack • 1 Jun 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals